trial · primary record
Gemcitabine + Ivonescimab
NSCLC
| Phase | Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 47 |
| Primary completion | 2029-07-31 |
| Primary endpoint | Objective response rate (ORR) according to RECIST v1.1 |
| Registry ID | NCT07158489 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:39:33.093Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07158489
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.